| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 17962510 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 117 journal articles in the PubMed database | Email to a friend | | |
| Garcia-Manero G, Yang H, Bueso-Ramos C, et al.
Phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced leukemias and myelodysplastic syndromes. [JOURNAL ARTICLE]
Blood 2007 Oct 25.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Giles F, Fischer T, Cortes J, et al.
A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies. [Journal Article]
Clin Cancer Res 2006 Aug 1; 12(15):4628-35.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | O'Connor OA, Heaney ML, Schwartz L, et al.
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. [Journal Article]
J Clin Oncol 2006 Jan 1; 24(1):166-73.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Blumenschein GR, Kies MS, Papadimitrakopoulou VA, et al.
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinzatrade mark, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. [JOURNAL ARTICLE]
Invest New Drugs 2007 Oct 25.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Crump M, Coiffier B, Jacobsen ED, et al.
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. [JOURNAL ARTICLE]
Ann Oncol 2008 Feb 21.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Duvic M, Talpur R, Ni X, et al.
Phase II Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) for Refractory Cutaneous T-cell Lymphoma (CTCL). [JOURNAL ARTICLE]
Blood 2006 Sep 7.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Richardson P, Mitsiades C, Colson K, et al.
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. [Journal Article]
Leuk Lymphoma 2008 Mar; 49(3):502-7.
Abstract | Full Citation | | Kelly WK, O'Connor OA, Krug LM, et al.
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. [Clinical Trial, Clinical Trial, Phase I, Journal Article]
J Clin Oncol 2005 Jun 10; 23(17):3923-31.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Mann BS, Johnson JR, Cohen MH, et al.
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma. [JOURNAL ARTICLE]
Oncologist 2007; 12(10):1247-1252.
Abstract | Full Citation |   |
|
| |
Advertise on this site.
|
New! 